Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31088263 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDLMNATSHRL3MBTL1 | |
| SCHEMBL30906634 | 0.82 | BACE1 (0.40) | SMN1; SMN2HPGDLMNATSHRL3MBTL1 | |
| SCHEMBL868296 | 0.82 | BACE1 (0.40) | SMN1; SMN2HPGDLMNATSHRL3MBTL1 | |
| Alcohol SCHEMBL5043640 | 0.81 | PTGDR2 (0.41) | SMN1; SMN2HPGDLMNATSHRALDH1A1 | |
| SCHEMBL17376656 | 0.79 | TYR (0.39) | SMN1; SMN2LMNATSHRL3MBTL1POLB | |
| SCHEMBL30087221 | 0.79 | CYP2A6 (0.32) | HPGDTSHRL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL2556376 | 0.79 | CYP2A6 (0.32) | HPGDTSHRL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL7787482 | 0.78 | GABRA1 (0.44) | SMN1; SMN2HPGDLMNATSHRL3MBTL1 | |
| SCHEMBL134773 | 0.78 | CCR5 (0.48) | SMN1; SMN2HPGDLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL12097459 | 0.77 | CCR5 (0.31) | TSHRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12522569-B2 | Substituted benzimidazole derivative and use thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-3730590-B1 | LIQUID CRYSTAL MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GMBH (DE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240279550-A1 | REACTIVE MESOGENS | MERCK PATENT GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| CN-109943349-B | Liquid-crystalline medium with homeotropic alignment | 默克专利股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024101402-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-113912547-B | Substituted benzene imidazole derivative and application thereof | 成都凡诺西生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4334408-A1 | REACTIVE MESOGENS | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-2032548-A1 | THIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1971582-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008096218-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008079836-A2 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | HOFFMANN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-6673267-B2 | EXHIBING HIGH REFRACTIVE INDEX ANISOTROPY; PHOTOSTABILITY; USEFUL IN PRODUCING COLORED FILMS, DISPLAYS, OPTICAL RECORDING MATERIALS, OPTICAL COMPENSATORS, POLARIZERS, REFLECTOR PLATES, AND SCATTERING PLATES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| US-20020006479-A1 | Phenylacetylene compound, liquid crystal composition, polymer, optically anisotropic product, and liquid crystal or optical element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279550-A1 | REACTIVE MESOGENS | MCHR1, MCHR2, OPRM1 | SMN1; SMN2 2929/4885HPGD 1196/4885LMNA 3584/4885 |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | FBP1, PFKFB1, PFKFB3 | SMN1; SMN2 3284/4885HPGD 2514/4885LMNA 4559/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | SMN1; SMN2 3845/4885HPGD 3525/4885LMNA 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.